Navitor Pharmaceuticals, Inc., a biopharmaceutical company developing innovative therapeutics targeting the activity of mTORC1, or Complex 1 of the mechanistic target of rapamycin, for neurological disorders and chronic diseases of aging, today announced that Thomas E. Hughes, Ph.D., Chief Executive Officer, will present a corporate overview at the 30th Annual Piper Jaffray Healthcare Conference.
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Navitor Pharmaceuticals Inc., a biopharmaceutical company developing innovative therapeutics targeting the activity of mTORC1, or Complex 1 of the mechanistic target of rapamycin, for neurological disorders and chronic diseases of aging, today announced that Thomas E. Hughes, Ph.D., Chief Executive Officer, will present a corporate overview at the 30th Annual Piper Jaffray Healthcare Conference in New York on Tuesday, November 27, 2018 at 1:10 p.m. Eastern time.
About Navitor
Navitor Pharmaceuticals, Inc.is realizing the potential of modulating mTORC1, a master regulator of cellular metabolism, to develop a pipeline of therapeutics that help patients live longer and healthier lives. Our industry-leading team is unlocking the promise of recent discoveries in mTORC1 biology to address a broad range of chronic diseases. Our initial clinical application is a first-in-class drug to address unmet needs in severe depression. For more information, please visit www.navitorpharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181120005702/en/
Contacts
Argot Partners
Laura Perry
Stephanie Marks
212-600-1902
laura@argotpartners.com
stephanie@argotpartners.com
Source: Navitor Pharmaceuticals, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20181120005702/en
